Advances in Pharmaceutical Suppressants and Expectorants
The OTC market in 2026 is divided into two functional categories: Antitussives and Expectorants. Antitussives, such as dextromethorphan (DM), target the brain's cough center to suppress the urge to cough, making them ideal for "dry, hacking" coughs that prevent sleep.
Conversely, expectorants like Guaifenesin are designed for "wet" or productive coughs; they work by increasing the volume and reducing the viscosity of respiratory tract secretions, making it easier for the patient to clear phlegm from the lungs. Modern 2026 formulations now utilize extended-release "mucoadhesive" syrups that cling to the throat for up to 12 hours, providing a localized, long-lasting barrier against the environmental triggers that exacerbate airway hypersensitivity.